3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
9
Lymphoma, Mantle-Cell
8
Breast Neoplasms
7
Lymphoma
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, T-Cell
5
Lymphoma, Non-Hodgkin
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Follicular
5
Lymphoma, B-Cell, Marginal Zone
5
Lymphoma, B-Cell
5
Recurrence
4
Neuroblastoma
4
Myelodysplastic Syndromes
4
Mycosis Fungoides
4
Multiple Myeloma
4
Lymphoma, T-Cell, Cutaneous
4
Leukemia
4
Congenital Abnormalities
4
Carcinoma, Non-Small-Cell Lung
4
Brain Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Leukemia, Myelomonocytic, Acute
3
Leukemia, Monocytic, Acute
3
Leukemia, Megakaryoblastic, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia, Erythroblastic, Acute
3
Glioblastoma
3
Burkitt Lymphoma
3
Interventions
pembrolizumab
5
Nivolumab
4
Cisplatin
4
Paclitaxel
3
Ifosfamide
3
avelumab
2
aldesleukin
2
Radiotherapy
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
vinflunine
1
toripalimab
1
rocakinogene sifuplasmid
1
niraparib
1
nimotuzumab
1
lenvatinib
1
fludarabine phosphate
1
fludarabine
1
enfortumab vedotin
1
durvalumab
1
dostarlimab
1
dacomitinib
1
cemiplimab
1
cabozantinib
1
cabazitaxel
1
Vorinostat
1
VGX-3100
1
Specimen Handling
1
Ritonavir
1
Neoadjuvant Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Penile Neoplasms
×
Vorinostat
×
Clear all
NCT04357873
2025-02-19
PEVOsq
UNICANCER
Phase 2
Completed
112 enrolled